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While clinicians continue to redeﬁ ne ventilator-asso-
ciated pneumonia (VAP), numerous innovations that 
claim to reduce pulmonary microaspiration and its 
consequences – that is, novel endotracheal cuﬀ  shapes 
and cuﬀ  materials, subglottic drainage, automatic cuﬀ 
pressure controllers, oral anti-septics, selective digestive 
decontamination (SDD), and devices to combat bioﬁ lm 
formation within the lumen of the tracheal tube – are 
coming to the market [1,2]. Th ere are two questions that 
clinicians ask when deciding whether to incorporate a 
new product or intervention into a VAP prevention 
bundle. Firstly, what are its eﬃ  cacy and eﬀ ectiveness? In 
other words, what is the relative risk reduction (RRR) and 
therefore the number needed to treat (NNT) to prevent 
one additional VAP. Secondly, is this new intervention 
cost-eﬀ ective in my local patients?
To answer the ﬁ rst question, one needs data from 
clinical trials and the knowledge of the baseline VAP rate 
with the likely RRR of the local case mix. We have 
calculated (Table  1) the NNT required to prevent one 
additional VAP for patients who require intubation and 
mechanical ventilation (MV) for more than 72 hours and 
an average time of MV of 10 days. Th e NNTs are based 
on an RRR ranging from 5% to 50% and a control event 
rate for VAP ranging from 1% to 20%, given a uniform 
distribution of NNTs across the range of RRRs. For 
example, with a VAP rate of approximately 8% and an 
intervention that reduces VAP by 45%, the NNT is 28 – a 
scenario that is realistic given a recent meta-analysis of 
one particular intervention [3].
To establish whether the intervention is cost-eﬀ ective, 
further knowledge of the cost of the intervention and the 
cost to treat an episode of VAP is required. A recent US 
study estimated the cost of VAP to be nearly $40,000 
(£25,000 or €30,000) [4]. If costs are assumed to be lower 
in Europe, then a conservative estimate of the cost per 
episode of VAP would still be around £10,000, which is 
equivalent to an extra 7 days of intensive care unit (ICU) 
stay. What should we consider when assessing the cost-
eﬀ ectiveness of VAP prevention?
We have calculated (Table 2) the additional money (in 
pounds) that can be spent to prevent an episode of VAP 
(per 10  days of MV) to achieve cost-neutrality. If we 
assume a hypothetical VAP cost of £10,000, then with a 
VAP rate of 8% and an RRR of 45%, it is cost-eﬀ ective to 
spend up to £360. Furthermore, even for an ICU with a 
VAP rate of only 4% and an intervention that reduces 
VAP by just 25%, it is still cost-eﬀ ective to spend up to 
£100 per 10  days of MV. It should be noted that some 
VAP prevention interventions (for example, a modiﬁ ed 
tracheal tube cuﬀ ) require just a ‘one-oﬀ ’ initial cost 
whereas other interventions (for example, SDD) require 
an ‘ongoing’ daily cost.
We think that this analysis might help clinicians in 
making the important economic decision of whether to 
adopt a new VAP prevention device or procedure. Our 
calculations can easily be adapted to local currencies and 
circumstances worldwide.
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Table 1. Number needed to treat in ventilator-associated pneumonia
                    Relative risk reduction
 5% 10% 15% 20% 25% 30% 35% 40% 45% 50%
Baseline VAP rate
 1% 2,000 1,000 667 500 400 333 286 250 222 200
 2% 1,000 500 333 250 200 167 143 125 111 100
 4% 500 250 167 125 100 83 71 63 56 50
 6% 333 167 111 83 67 56 48 42 37 33
 8% 250 125 83 63 50 42 36 31 28 25
 10% 200 100 67 50 40 33 29 25 22 20
 15% 133 67 44 33 27 22 19 16.7 15 13
 20% 100 50 33 25 20 17 14 12.5 11 10
Number needed to treat (NNT) was calculated as: NNT [relative risk of event] = 1 / (pc × RRR), where pc is the proportion of control group subjects who suff er an event 
and RRR is relative risk reduction. These NNTs are based on events per 10 days of mechanical ventilation, meaning that more than one event can occur in a single 
patient who is ventilated for more than 10 days. VAP, ventilator-associated pneumonia.
Table 2. Cost-eff ectiveness of an intervention based on baseline ventilator-associated pneumonia rate and its relative 
risk reduction
                     Relative risk reduction
  5% 10% 15% 20% 25% 30% 35% 40% 45% 50%
Baseline VAP rate
 1% £5 £10 £15 £20 £25 £30 £35 £40 £45 £50
 2% £10 £20 £30 £40 £50 £60 £70 £80 £90 £100
 4% £20 £40 £60 £80 £100 £120 £140 £160 £180 £200
 6% £30 £60 £90 £120 £150 £180 £210 £240 £270 £300
 8% £40 £80 £120 £160 £200 £240 £280 £320 £360 £400
 10% £50 £100 £150 £200 £250 £300 £350 £400 £450 £500
 15% £75 £150 £225 £300 £375 £450 £525 £600 £675 £750
 20% £100 £200 £300 £400 £500 £600 £700 £800 £900 £1,000
Values (£) refer to the average additional expense that can be spent for an intervention, per 10 days of mechanical ventilation, for it to be cost-neutral assuming a 
ventilator-associated pneumonia (VAP) cost of £10,000.
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